AZ Turnhout

Turnhout 2900

0 studies enrolling now · 6 studies all time

What they study most

Acute Coronary Syndrome, Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN), Atrial Fibrillation, Endometrial Cancer, Heart Failure, Myelodysplastic Syndromes, Relapsed or Refractory Acute Myeloid Leukemia (AML)

Studies at this site

• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] — Completed
• Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment — Completed
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) — Stopped early
• A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction — Completed